Manage your personalised Watchlist.Set up an online Virtual Portfolio.Participate in Share Chat.See more trades and director dealings.Play the Fantasy Share Trading Game.
Register for FREE Now
The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
jimmyLondon
Posted in: SNG
Posts: 175
Price: 187.00
No Opinion
Let's have a human challenge trial with a therapeutic that has shown to be questionable in effectiveness (remdesivir) as back-up. What can go wrong?
Price: 226.00
100,000 per month doesn't seem like a lot given the population in Europe and US.
Price: 223.00
yeeee hahhhhh giddyup!!!! Riding this thoroughbred to retirement!
Price: 190.00
https://www.msn.com/en-gb/news/coronavirus/coronavirus-antibodies-fade-after-only-a-month-study-shows/ar-BB18UjM3?ocid=chromentpnews
Price: 192.00
Given the worrying news relating to the AstraZ/Oxford trial, one would have thought that safe therapeutics would be attractive.
Price: 208.00
With approx $180 million AUM, their exposure to SNG is less than 0.3%. This must be coming from their discretionary budget away from their benchmark.
I share your sentiment re the need for humility. Being giddy about making money on a vaccine or therapy for something that has killed 100's of thousands and put millions of our fellow citizens out of work is plainly crass.
Login failed